

Paul J Carter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1367021/publications.pdf>

Version: 2024-02-01

41
papers

7,689
citations

201674

27
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

7782
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent antibody therapeutics by design. <i>Nature Reviews Immunology</i> , 2006, 6, 343-357.	22.7	1,013
2	Therapeutic antibodies for autoimmunity and inflammation. <i>Nature Reviews Immunology</i> , 2010, 10, 301-316.	22.7	748
3	Dissecting the catalytic triad of a serine protease. <i>Nature</i> , 1988, 332, 564-568.	27.8	638
4	“Knobs-into-holes”™ engineering of antibody C _H 3 domains for heavy chain heterodimerization. <i>Protein Engineering, Design and Selection</i> , 1996, 9, 617-621.	2.1	616
5	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	46.4	595
6	Alternative molecular formats and therapeutic applications for bispecific antibodies. <i>Molecular Immunology</i> , 2015, 67, 95-106.	2.2	503
7	Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro. <i>Biochemistry</i> , 1997, 36, 66-75.	2.5	412
8	An efficient route to human bispecific IgG. <i>Nature Biotechnology</i> , 1998, 16, 677-681.	17.5	406
9	Introduction to current and future protein therapeutics: A protein engineering perspective. <i>Experimental Cell Research</i> , 2011, 317, 1261-1269.	2.6	400
10	Antibody-Drug Conjugates for Cancer Therapy. <i>Cancer Journal (Sudbury, Mass.)</i> , 2008, 14, 154-169.	2.0	356
11	High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment. <i>Nature Biotechnology</i> , 1992, 10, 163-167.	17.5	258
12	Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. <i>Journal of Molecular Biology</i> , 1997, 270, 26-35.	4.2	224
13	X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2 Antibody 4D5 and Comparison with Molecular Modeling. <i>Journal of Molecular Biology</i> , 1993, 229, 969-995.	4.2	185
14	Bispecific human IgG by design. <i>Journal of Immunological Methods</i> , 2001, 248, 7-15.	1.4	156
15	Engineering subtilisin BPN [®] 2 for site-specific proteolysis. <i>Proteins: Structure, Function and Bioinformatics</i> , 1989, 6, 240-248.	2.6	112
16	Substrate-assisted catalysis: Molecular basis and biological significance. <i>Protein Science</i> , 2000, 9, 1-9.	7.6	112
17	Anti-CD30 diabody-drug conjugates with potent antitumor activity. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2486-2497.	4.1	109
18	Antibody engineering. <i>Current Opinion in Structural Biology</i> , 1998, 8, 443-450.	5.7	98

#	ARTICLE	IF	CITATIONS
19	High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli. Nature Biotechnology, 1996, 14, 192-196.	17.5	92
20	Remodeling domain interfaces to enhance heterodimer formation. Protein Science, 1997, 6, 781-788.	7.6	85
21	Probing the mechanism and improving the rate of substrate-assisted catalysis in subtilisin BPN'. Biochemistry, 1991, 30, 6142-6148.	2.5	76
22	Binding interactions of kistrin with platelet glycoprotein IIb/IIIa: Analysis by site-directed mutagenesis. Proteins: Structure, Function and Bioinformatics, 1993, 15, 312-321.	2.6	74
23	Engineering antibodies for imaging and therapy. Current Opinion in Biotechnology, 1997, 8, 449-454.	6.6	68
24	Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs, 2017, 9, 213-230.	5.2	60
25	Toward the Production of Bispecific Antibody Fragments for Clinical Applications. Stem Cells and Development, 1995, 4, 463-470.	1.0	44
26	Characterization of Chain Pairing Variants of Bispecific IgG Expressed in a Single Host Cell by High-Resolution Native and Denaturing Mass Spectrometry. Analytical Chemistry, 2016, 88, 12122-12127.	6.5	39
27	Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry. MAbs, 2016, 8, 1467-1476.	5.2	33
28	Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies. MAbs, 2020, 12, 1692764.	5.2	27
29	Site-Specific Proteolysis of Fusion Proteins. ACS Symposium Series, 1990, , 181-193.	0.5	24
30	Engineering linear F(ab') ₂ fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Engineering, Design and Selection, 1995, 8, 1057-1062.	2.1	20
31	Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells. MAbs, 2019, 11, 1254-1265.	5.2	19
32	Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. Molecular Immunology, 1994, 31, 1335-1344.	2.2	17
33	Therapeutic antibodies: Discovery, design and deployment. Molecular Immunology, 2015, 67, 1-3.	2.2	16
34	Single cell-produced and <i>in vitro</i> -assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar <i>in vitro</i> and <i>in vivo</i> properties. MAbs, 2019, 11, 422-433.	5.2	14
35	Characterization of bispecific and mispaired IgGs by native charge-variant mass spectrometry. International Journal of Mass Spectrometry, 2019, 446, 116229.	1.5	10
36	Data on charge separation of bispecific and mispaired IgGs using native charge-variant mass spectrometry. Data in Brief, 2020, 30, 105435.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Structural Analysis and Optimization of Context-Independent Anti-Hypusine Antibodies. Journal of Molecular Biology, 2016, 428, 603-617.	4.2	8
38	Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs, 2016, 8, 617-652.	5.2	7
39	Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Molecular Cancer Therapeutics, 2015, 14, 2270-2278.	4.1	6
40	The Rise of Antibodies as Therapeutics. Lung Biology in Health and Disease, 2002, , 427-469.	0.1	0
41	Antibody engineering-IBC's Tenth International Conference. 6-9 December 1999, La Jolla, CA, USA. IDrugs: the Investigational Drugs Journal, 2000, 3, 259-61.	0.7	0